Gengraf

Base Information

• Chemical Name: Gengraf
• CAS No.: 79217-60-0
• Molecular Formula: C62H111N11O12
• Molecular Weight: 1202.61
• European Community (EC) Number: 611-907-1
• Wikipedia: Ciclosporin
• NCI Thesaurus Code: C406
• RXCUI: 3008
• Mol file: 79217-60-0.mol

Synonyms:Ciclosporin;CsA Neoral;CsA-Neoral;CsANeoral;CyA NOF;CyA-NOF;Cyclosporin;Cyclosporin A;Cyclosporine;Cyclosporine A;Neoral;OL 27 400;OL 27-400;OL 27400;Sandimmun;Sandimmun Neoral;Sandimmune

Chemical Property of Gengraf

Chemical Property:

• Appearance/Colour: White Powder
• Vapor Pressure: 0mmHg at 25°C
• Melting Point: 148-151oC
• Refractive Index: 1.467
• Boiling Point: 1293.8 °C at 760 mmHg
• Flash Point: 736.3 °C
• PSA: 292.76000
• Density: 1.016 g/cm³
• LogP: 3.93790
• XLogP3: 7.5
• Hydrogen Bond Donor Count: 5
• Hydrogen Bond Acceptor Count: 12
• Rotatable Bond Count: 15
• Exact Mass: 1201.84136802
• Heavy Atom Count: 85
• Complexity: 2330

Purity/Quality:

99% ^*data from raw suppliers

Cyclosporine(Neoral) >99% ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T,Xn
• Hazard Codes: T,Xn

MSDS Files:

SDS file from LookChem

Useful:

• Chemical Classes: Biological Agents -> Mycotoxins
• Drug Classes: Dermatologic Agents; Transplant Agents
• Canonical SMILES: CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
• Isomeric SMILES: CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
• Recent ClinicalTrials: A Trial for Acute Severe Ulcerative Colitis
• Recent EU Clinical Trials: RANDOMIZED PARALLEL CLINICAL TRIAL TO DETERMINE THE EFFECTIVENESS AND SAFETY OF TOPICAL INSULIN IN THE TREATMENT OF DRY EYE IN PATIENTS WITH DRY EYE
• Recent NIPH Clinical Trials: EMaCy trial
• Description: Cyclosporine is a cyclic polypeptide with potent, partially selective immunosupressive activity. Isolated from the species Cylindrocarpon lucidium and Trichoderma polysporum, cyclosporine is useful in the prevention and treatment of graft/host disease and the prevention of rejection following organ transplantation. It appears to act by preferentially suppressing T-lymphocytes. Cyclosporine lacks myelotoxicity, although impaired renal and liver function have been observed. Initial administration is via the intravenous route, followed by oral maintenance therapy.
• Indications: Cyclosporine (Sandimmune) is a potent inhibitor of antibody- and cell-mediated immune responses and is the immunosuppressant of choice for the prevention of transplant rejection. It also has application in the treatment of autoimmune diseases. Cyclosporine is a highly stable 11-amino acid cyclic polypeptide. The molecule is very lipophilic and essentially is not soluble in water. It can be administered intravenously, orally, or by injection.
• Clinical Use: Cyclosporine has been approved for use in allogeneic kidney, liver, and heart transplant patients and is under study for use in pancreas, bone marrow, single lung, and heart–lung transplant procedures. It is recommended that corticosteroids, such as prednisone, be used concomitantly, although at half or less of their usual dose. Such combined therapy leads to fewer side effects, a decreased incidence of infectious complications, efficacy of lower doses of cyclosporine, and a better history of patient survival. Cyclosporine appears to have promise in the treatment of autoimmune diseases. It has a beneficial effect on the course of rheumatoid arthritis, uveitis, insulindependent diabetes, systemic lupus erythematosus, and psoriatic arthropathies in some patients. Toxicity is more of a problem in these conditions than during use in transplantation, since higher doses of cyclosporine are often required to suppress autoimmune disorders.